Effects of recurrent intra-articular corticosteroid injections for osteoarthritis at 3 months and beyond: a systematic review and meta-analysis in comparison to other injectables

Intra-articular corticosteroid injections (IACIs) provide temporary symptom relief in osteoarthritis (OA). This meta-analysis investigated the effects of recurrent IACIs at 3 months and beyond. We searched Medline, Embase and Cochrane from inception to January 2021 for randomised controlled trials (...

Full description

Saved in:

Bibliographic Details
Published in:	Osteoarthritis and cartilage Vol. 30; no. 12; pp. 1658 - 1669
Main Authors:	Donovan, R.L., Edwards, T.A., Judge, A., Blom, A.W., Kunutsor, S.K., Whitehouse, M.R.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-12-2022
Subjects:	Adrenal Cortex Hormones - therapeutic use Humans Hyaluronic Acid Injections, Intra-Articular Meta-analysis Osteoarthritis Osteoarthritis, Knee - therapy Pain - drug therapy Patient reported outcome measures Platelet-Rich Plasma Steroids Systematic review Treatment Outcome Patient reported outcome measures Injections, Intra-articular Systematic review Osteoarthritis Steroids Meta-analysis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Intra-articular corticosteroid injections (IACIs) provide temporary symptom relief in osteoarthritis (OA). This meta-analysis investigated the effects of recurrent IACIs at 3 months and beyond. We searched Medline, Embase and Cochrane from inception to January 2021 for randomised controlled trials (RCTs) of patients with OA who received recurrent IACIs compared with other injectables, placebo or no treatment (primary outcomes: pain, function). Mean differences (MDs) with 95% confidence intervals were reported. Ten RCTs were included (eight knee OA (n = 763), two trapeziometacarpal OA (n = 121)). Patients received between 2 and 8 injections, varying by trial. Trials compared recurrent IACIs with hyaluronic acid (HA), platelet-rich plasma (PRP), saline or orgotein (follow-up 3–24 months). Greater improvements in pain, function and QoL at 3–24 months were noted for the comparators than with IACIs, with comparators demonstrating an equal or superior effect, or the intervention effect attenuated during follow-up. Recurrent IACIs demonstrated no benefits in pain or function over placebo at 12–24 months. No serious adverse events were recorded. No studies reported on time-to-future interventions, risk of future prosthetic joint infection or other adverse events associated with subsequent joint replacement. Recurrent IACIs often provide inferior (or non-superior) symptom relief compared with other injectables (including placebo) at 3 months and beyond. Other injectables (HA, PRP) often yielded greater improvements in pain and function up to 24 months post-injection. Existing RCTs on recurrent IACIs lack sufficient follow-up data to assess disease progression and time-to-future interventions.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	1063-4584 1522-9653
DOI:	10.1016/j.joca.2022.07.011